Patents by Inventor Mervyn Maze

Mervyn Maze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170342020
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: June 5, 2017
    Publication date: November 30, 2017
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Patent number: 9708247
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 18, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Publication number: 20160333088
    Abstract: The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.
    Type: Application
    Filed: March 8, 2016
    Publication date: November 17, 2016
    Inventors: Mervyn Maze, Marc Feldman, Niccolo Terrando, Mario Cibelli, Daqing Ma, Michael Fertleman
  • Patent number: 9326996
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: May 3, 2016
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 9308254
    Abstract: The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: April 12, 2016
    Assignee: IMPERIAL INNOVATIONS LIMITED
    Inventors: Mervyn Maze, Marc Feldman, Niccolo Terrando, Mario Cibelli, Daqing Ma, Michael Fertleman
  • Publication number: 20160096800
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: September 9, 2015
    Publication date: April 7, 2016
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Publication number: 20150216897
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
    Type: Application
    Filed: February 10, 2015
    Publication date: August 6, 2015
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Publication number: 20130084299
    Abstract: The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.
    Type: Application
    Filed: February 17, 2011
    Publication date: April 4, 2013
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Mervyn Maze, Marc Feldman, Niccolo Terrando, Mario Cibelli, Daqing Ma, Michael Fertleman
  • Publication number: 20100316729
    Abstract: Noble gases, in particular xenon and/or helium, administered under hyperbaric conditions of less than 3 atm (0.3 MPa), are used to provide neuroprotection, in particular in patients having suffered an impact trauma to the head and/or spinal column.
    Type: Application
    Filed: April 9, 2008
    Publication date: December 16, 2010
    Applicant: AIR PRODUCTS AND CHEMICALS, INC.
    Inventors: Nicholas Peter Franks, Mervyn Maze, Juan Carlos Sacristan Martin
  • Publication number: 20090311340
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
    Type: Application
    Filed: August 19, 2005
    Publication date: December 17, 2009
    Applicant: PROTEXEON LIMITED
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 7632872
    Abstract: In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon. In a third aspect, the invention relates to a method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and fetal subject.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: December 15, 2009
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Publication number: 20090252814
    Abstract: Use of xenon is described. Xenon is used as an organ and/or tissue and/or cell protectant in the manufacture of a pharmaceutical for the protection from injury of organs and/or tissue and/or cells that express HIF.
    Type: Application
    Filed: October 3, 2006
    Publication date: October 8, 2009
    Inventors: Mervyn Maze, Patrick Henry Maxwell, David Edwards
  • Patent number: 7442383
    Abstract: The present invention relates to methods of controlling neurological deficits in patients who have undergone cardiopulmonary bypass (CPB) by administering xenon to said patients.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: October 28, 2008
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 7390508
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for the treatment of neonatal asphyxia in a neonatal subject, wherein said medicament is for use in combination with hypothermia.
    Type: Grant
    Filed: October 11, 2004
    Date of Patent: June 24, 2008
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Publication number: 20070104796
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for the treatment of neonatal asphyxia in a neonatal subject, wherein said medicament is for use in combination with hypothermia.
    Type: Application
    Filed: October 11, 2004
    Publication date: May 10, 2007
    Applicant: PROTEXEON LIMITED
    Inventors: Nicholas Franks, Mervyn Maze
  • Publication number: 20060233885
    Abstract: In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon. In a third aspect, the invention relates to a method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and fetal subject.
    Type: Application
    Filed: August 5, 2003
    Publication date: October 19, 2006
    Inventors: Nicholas Franks, Mervyn Maze
  • Publication number: 20050238726
    Abstract: The present invention relates to methods of controlling neurological deficits in patients who have undergone cardiopulmonary bypass (CPB) by administering xenon to said patients.
    Type: Application
    Filed: May 1, 2003
    Publication date: October 27, 2005
    Inventors: Nicholas Franks, Mervyn Maze
  • Publication number: 20050106184
    Abstract: Provided herein are mutant strains of Neisseria meningitidis which produce Kdo-free lipid A as well as the Kdo-free lipid A molecules and immunogenic compositions containing such Kdo-free lipid A molecules from a Neisseria strain containing a genetically stable mutation which inactivates a gene selected from the group consisting of genes encoding arabinose-5-phosphate isomerase, CMP-Kdo synthetase and CMP-Kdo transferase. N. meningitidis NMB206 is a specifically exemplified strain which harbors a stable insertion mutation in the gene (ApsF) encoding A5P isomerase; strain NMB-249 is a specifically exemplified strain with a stable insertion mutation in the gene (kdtA) encoding CMP-Kdo synthetase, and strain NMB259 is specifically exemplified strain with a stable insertion mutation in the gene (kdsB) encoding CMP-Kdo transferase. Also provided by the present invention are methods for the production of Lipid A flee of 3-keto-3-deoxyoctanoic acid using these genetically stable N. meningitidis mutants.
    Type: Application
    Filed: March 20, 2003
    Publication date: May 19, 2005
    Inventors: Nicholas Franks, Mervyn Maze
  • Patent number: 6653354
    Abstract: The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: November 25, 2003
    Assignee: Protexeon Limited
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 6567702
    Abstract: A method of eliciting analgesia in a human subject by Transcranial Electrical Stimulation (TCES) is provided. Electrodes are secured to the skin of the subject's head and used to apply an electrical current to the electrodes. The current includes a direct current combined with rectangular current pulses (alternating current) delivered at a frequency of between 30 and 65 Hz. The frequency at which the pulses are delivered is periodically changed to a different value within the 30-65 Hz range. The total current supplied, a sum of the DC component and a Mean Absolute Deviation (MAD) of the current pulses, preferably has a value between 0.2 and 20 mA. The method is used during surgery and the post-operative procedure, and may also be used to treat a wide variety of neurological and other conditions.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: May 20, 2003
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Vladimir Nekhendzy, Mervyn Maze